Journal of Pediatric Pharmacology and Therapeutics最新文献_第2页

Optimization of Medication Workflows to Improve Timely Medication Administration on a Pediatric Hospital Unit: A Quality Improvement Project. 优化用药流程，提高儿科医院及时用药管理：一个质量改进项目。

Journal of Pediatric Pharmacology and Therapeutics Pub Date : 2025-08-01 Epub Date: 2025-08-11 DOI: 10.5863/JPPT-23-00139

John C Standish, Laura Chapman, Ohsha Cloyd, Karan Johnson, Katie Mellody, Karlee Fisher, Cathy Gustavel, Michael Bigham

{"title":"Optimization of Medication Workflows to Improve Timely Medication Administration on a Pediatric Hospital Unit: A Quality Improvement Project.","authors":"John C Standish, Laura Chapman, Ohsha Cloyd, Karan Johnson, Katie Mellody, Karlee Fisher, Cathy Gustavel, Michael Bigham","doi":"10.5863/JPPT-23-00139","DOIUrl":"10.5863/JPPT-23-00139","url":null,"abstract":"Objective: Medication workflows are important to improve patient safety and provide timely lifesaving medical care. When operating efficiently, they can also decrease medication and labor waste. The objective of this quality improvement project is to compare missing dose request rates before and after improvements in medication workflows, specifically, decreases in medication and labor waste and the financial implications of these improvements.Methods: The study evaluated the rate of medication missing dose requests on a 24-bed medical surgical unit in a standalone pediatric hospital from May 2022 to October 2022. Medication workflows were evaluated by pharmacy and nursing team members, and interventions were identified and implemented with the Model for Improvement methodology. Outcomes of missing dose requests per 100 medication doses dispensed were tracked weekly, as were staff time and costs of medications.Results: The missing dose requests per 100 medication doses dispensed decreased from 3.8 to 1.03 during the 6-month initiative. This improvement estimated that 988 missing medication doses were prevented, leading to an estimated $61,038.64 in waste savings. The average cost of the medication and materials (excluding labor) to replace a single missing dose of medication was $61.78. The median cost was $54.71 (IQR, 11.91-4,213.11). Pharmacist, pharmacy technician, and nurse time saved per missing dose were estimated to be 6, 14, and 17 minutes, respectively.Conclusion: Multimodal improvements in inpatient medication workflow reduce missed medication errors and improve cost and labor efficiencies.","PeriodicalId":37484,"journal":{"name":"Journal of Pediatric Pharmacology and Therapeutics","volume":"30 4","pages":"476-483"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12351491/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144875683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pediatric Pharmacy Association 2025 KIDs List of Key Potentially Inappropriate Drugs in Pediatrics. 儿科药学协会2025年儿童儿科关键潜在不适宜药物清单。

Journal of Pediatric Pharmacology and Therapeutics Pub Date : 2025-08-01 Epub Date: 2025-08-11 DOI: 10.5863/JPPT-25-00061

Christopher McPherson, Rachel S Meyers, Jennifer Thackray, Danielle L Stutzman, Kimberly P Mills, Sana J Said, Karisma Patel, Robert C Hellinga, Amy L Potts, Lisa Lubsch, Kelly L Matson, David S Hoff

{"title":"Pediatric Pharmacy Association 2025 KIDs List of Key Potentially Inappropriate Drugs in Pediatrics.","authors":"Christopher McPherson, Rachel S Meyers, Jennifer Thackray, Danielle L Stutzman, Kimberly P Mills, Sana J Said, Karisma Patel, Robert C Hellinga, Amy L Potts, Lisa Lubsch, Kelly L Matson, David S Hoff","doi":"10.5863/JPPT-25-00061","DOIUrl":"10.5863/JPPT-25-00061","url":null,"abstract":"Objective: The objective was to update the KIDs List, a list of drugs and excipients that are potentially inappropriate for use in pediatric patients, accounting for emerging pharmacologic agents and published evidence.Methods: A panel of 12 pediatric pharmacists from the Pediatric Pharmacy Association (PPA) evaluated primary, secondary, and tertiary literature; FDA Pediatric Safety Communications; the UpToDate Lexidrug database; and product information for drugs that may be considered potentially inappropriate for use in pediatric patients. A PubMed search identified new publications from October 1, 2017, to November 1, 2023. All agents included in the previous publication and those anecdotally identified as candidates for the list by the authors or PPA members were evaluated. Evidence was reviewed by all authors. The draft list underwent a 30-day public comment period prior to being finalized.Results: A PubMed search yielded 917 unique titles of which 17 were deemed relevant for full review. Sixty-seven drugs and/or drug classes and 10 excipients from the original publication were also reviewed. Author and PPA member recommendations highlighted an additional 25 drugs or drug classes. The UpToDate Lexidrug database extraction yielded 1470 drugs, which were filtered to 145 agents for author review. After critical analysis and reorganization, the second edition of the KIDs List contains 39 drugs and/or drug classes and 10 excipients.Conclusions: This article updates the initial list of drugs and excipients that are potentially inappropriate for prescribing in all or a select subgroup of pediatric patients. The second edition should stimulate novel research to inform future updates.","PeriodicalId":37484,"journal":{"name":"Journal of Pediatric Pharmacology and Therapeutics","volume":"30 4","pages":"422-439"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12351480/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144875685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Use of Intrapleural Alteplase in the Treatment of Parapneumonic Effusion in Children: A Report of a 10-year Experience. 应用胸膜内阿替普酶治疗儿童肺旁积液：10年经验报告。

Journal of Pediatric Pharmacology and Therapeutics Pub Date : 2025-08-01 Epub Date: 2025-08-11 DOI: 10.5863/JPPT-24-00057

Yusuf M Garwan, Muath A Alsalloum, A Jill Thompson, Taylor Morrisette, Katherine H Chessman

{"title":"Use of Intrapleural Alteplase in the Treatment of Parapneumonic Effusion in Children: A Report of a 10-year Experience.","authors":"Yusuf M Garwan, Muath A Alsalloum, A Jill Thompson, Taylor Morrisette, Katherine H Chessman","doi":"10.5863/JPPT-24-00057","DOIUrl":"10.5863/JPPT-24-00057","url":null,"abstract":"Objectives: Intrapleural alteplase is used in children with parapneumonic effusion (PPE) with variable dosing strategies. We compared the outcomes of a lower (≤2 mg) and a higher (>2 mg) alteplase dose in children with PPE.Methods: A retrospective study was conducted among admitted patients younger than 18 years who received at least 1 intrapleural alteplase dose from July 2014 to May 2023. The primary outcome was the treatment failure rate. Secondary outcomes included chest tube output and duration of placement and hospital and pediatric intensive care unit (PICU) length of stays.Results: Seventy-two patients were included (lower dose: 62.5% vs higher dose: 37.5%) with a median age of 5 years (IQR, 1-8 years). The median alteplase dose was 2 mg (IQR, 2-4 mg). Treatment failure occurred in 10 (14%) patients. The lower dose group had a similar failure rate compared with the higher dose group (lower dose: 9% vs higher dose: 22%; p = 0.161), despite a statistically significant higher median chest tube output in the higher dose group (346 [IQR, 256-466] vs 175 [IQR, 70-358] mL/24h; p = 0.002). However, after adjusting for weight, both groups had a similar output (12 mL/kg/24h). Alteplase instillation after primary video-assisted thoracoscopic surgery (VATS) was associated with a significant reduction in the duration of chest tube placement and hospital and PICU stays.Conclusions: Lower alteplase doses (≤2 mg) were effective for most children with PPE. Alteplase combined with primary VATS might be associated with better outcomes.","PeriodicalId":37484,"journal":{"name":"Journal of Pediatric Pharmacology and Therapeutics","volume":"30 4","pages":"484-493"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12351476/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144875689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of Pharmacist-To-Dose Enoxaparin in Pediatric Patients. 依诺肝素对儿科患者的影响。

Journal of Pediatric Pharmacology and Therapeutics Pub Date : 2025-08-01 Epub Date: 2025-08-11 DOI: 10.5863/JPPT-24-00072

Yi Fei Heng, Andrew Allison, Emily Clemons

{"title":"Impact of Pharmacist-To-Dose Enoxaparin in Pediatric Patients.","authors":"Yi Fei Heng, Andrew Allison, Emily Clemons","doi":"10.5863/JPPT-24-00072","DOIUrl":"10.5863/JPPT-24-00072","url":null,"abstract":"Objective: Variations in pharmacokinetics necessitate monitoring anti-Xa concentrations for optimal anticoagulation in pediatric patients receiving enoxaparin for the prophylaxis or treatment of venous thromboembolism. Pharmacists play an essential role through pharmacist-to-dose (PTD) protocols. This study aims to assess the impact of pharmacist involvement by comparing rates of achieving target anti-Xa concentrations before and after implementation of the PTD protocol in a pediatric population.Methods: Medical records were queried for patients 18 years old and younger who received enoxaparin as an inpatient at West Virginia University Medicine Children's Hospital from January 2016 to September 2023. Indication, dosing, and administration of enoxaparin were assessed. Anti-Xa concentrations were evaluated for appropriate timing and goal range. Secondary outcomes included the number of anti-Xa concentrations drawn, the number of enoxaparin dose adjustments, the rate of accurately drawn anti-Xa concentrations, the rate of following guideline recommended enoxaparin dosing on initiation, and the time to goal anti-Xa concentration.Results: There was no difference in the rate of anti-Xa concentrations that were in goal before and after the implementation of a pharmacist-led enoxaparin dosing protocol. The frequency of concentrations drawn appropriately was higher, and the time to goal was shorter after the implementation of the PTD protocol, although this difference was not statistically significant.Conclusions: There was no difference in the rate of anti-Xa concentrations that were in goal between groups. This likely stemmed from the use of the same dose adjustment guideline among both groups. This underscores the equal quality of care provided by pharmacists in achieving optimal anticoagulation and positive outcomes.","PeriodicalId":37484,"journal":{"name":"Journal of Pediatric Pharmacology and Therapeutics","volume":"30 4","pages":"471-475"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12359062/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144883963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pediatric Pharmacists' Participation in Cardiopulmonary Resuscitation Events. 儿科药师参与心肺复苏事件的情况。

Journal of Pediatric Pharmacology and Therapeutics Pub Date : 2025-08-01 Epub Date: 2025-08-11 DOI: 10.5863/JPPT-25-00045

Olivia Brandner, Lauren Campisi, Amy L Nguyen

{"title":"Pediatric Pharmacists' Participation in Cardiopulmonary Resuscitation Events.","authors":"Olivia Brandner, Lauren Campisi, Amy L Nguyen","doi":"10.5863/JPPT-25-00045","DOIUrl":"10.5863/JPPT-25-00045","url":null,"abstract":"The Pediatric Pharmacy Association (PPA) understands the dilemma and varying factors that many institutions face concerning the routine participation of pharmacists in emergency resuscitation. Acknowledging these challenges, the PPA encourages all institutions to strongly consider creating, adopting, and upholding policies to address pharmacists' participation in cardiopulmonary resuscitation (CPR) events. The PPA advocates that pharmacists be actively involved in the institution's medical emergency team committees and the preparation of emergency drug kits and resuscitation trays. The PPA advocates that all institutions requiring a pharmacist's participation in CPR events consider adopting preparatory training programs. The PPA recommends that pharmacists obtain emergency response credentialling with basic life support and pediatric advanced life support and may consider advanced cardiac life support and neonatal resuscitation program certification dependent on practice area. Additionally, the PPA recommends that pharmacists are educated on the pharmacotherapy of drugs used in the CPR process, including, but not limited to, medication preparation and administration guidelines, medication compatibility, recommended dosing for emergency medications, and familiarity with the institutional emergency cart.","PeriodicalId":37484,"journal":{"name":"Journal of Pediatric Pharmacology and Therapeutics","volume":"30 4","pages":"520-525"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12351459/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144875684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Daptomycin Experience in the Pediatric and Neonatal Population: A Systematic Review. 达托霉素在儿童和新生儿中的应用：一项系统综述。

Journal of Pediatric Pharmacology and Therapeutics Pub Date : 2025-08-01 Epub Date: 2025-08-11 DOI: 10.5863/JPPT-24-00056

Robyn Yarsley, Benjamin M Lopez, Gabriela Alves, Fabio Aguiar-Alves

引用次数: 0

Microbial Biofilms: Where Are We and Where Are We Going? 微生物生物膜：我们在哪里，我们要去哪里？

Journal of Pediatric Pharmacology and Therapeutics Pub Date : 2025-08-01 Epub Date: 2025-08-11 DOI: 10.5863/JPPT-25-01211

Sudi Shatha Harbool, Mahmoud Ghannoum

引用次数: 0

Acne Vulgaris in Children and Adolescents: What's the Cause and How to Combat It. 儿童和青少年的寻常痤疮：原因是什么以及如何对抗它。

Journal of Pediatric Pharmacology and Therapeutics Pub Date : 2025-06-01 Epub Date: 2025-06-09 DOI: 10.5863/JPPT-25-01205

Sabina Alikhanov Palmieri

引用次数: 0

Evaluation of Patient-Driven Constipation Action Plans for Patients Discharged From a Pediatric Hospitalist Service. 评估患者驱动便秘行动计划的患者从儿科医院服务出院。

Journal of Pediatric Pharmacology and Therapeutics Pub Date : 2025-06-01 Epub Date: 2025-06-09 DOI: 10.5863/JPPT-24-00115

Zachary Kiss, Andrew Allison, Melissa Knopp

引用次数: 0

The Pitfalls and Opportunities With Posaconazole DR Oral Suspension. 泊沙康唑DR口服混悬液的缺陷与机遇。

Journal of Pediatric Pharmacology and Therapeutics Pub Date : 2025-06-01 Epub Date: 2025-06-09 DOI: 10.5863/JPPT-24-00018

Cassandra Rush, Ashley Duty

引用次数: 0